Education
About Us
Working with TipRanks
Follow Us
Ventana Global Inc (VNTAD)
:VNTAD
VNTAD Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)20.00
Market Cap
$11.29K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)16.7
Beta-3.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,753,350
10 Day Avg. Volume43
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.04
Price to Cash Flow (P/CF)41.80
P/FCF Ratio41.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
VNTAD FAQ
What was Ventana Global Inc’s price range in the past 12 months?
Currently, no data Available
What is Ventana Global Inc’s market cap?
Ventana Global Inc’s market cap is $11.29K.
When is Ventana Global Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ventana Global Inc’s earnings last quarter?
Currently, no data Available
Is Ventana Global Inc overvalued?
According to Wall Street analysts Ventana Global Inc’s price is currently Undervalued.
Does Ventana Global Inc pay dividends?
Ventana Global Inc does not currently pay dividends.
What is Ventana Global Inc’s EPS estimate?
Ventana Global Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ventana Global Inc have?
Ventana Global Inc has 2,753,350 shares outstanding.
What happened to Ventana Global Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ventana Global Inc?
Currently, no hedge funds are holding shares in VNTAD
---
Company Description
Ventana Global Inc
Ventana Biotech, Inc. is a bioscience company, which engages in the identifying, evaluating, acquiring, developing, and partnering to achieve commercialization of intellectual property in the area of drug candidates for personalized medicine. It focuses in the areas of anti-obesity and related illnesses. The company was founded on November 6, 1989 and is headquartered in Butschwil, Switzerland.
---
---